Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Published byGerald Arnold Modified over 5 years ago

Similar presentations

Presentation on theme: "Nat. Rev. Clin. Oncol. doi: /nrclinonc"— Presentation transcript:

1 Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.40
Figure 4 Stratification biomarkers to identify MET-dependent colorectal cancers (CRCs) Figure 4 | Stratification biomarkers to identify MET-dependent colorectal cancers (CRCs). a | MET to chromosome 7 double-silver in situ hybridization (DISH) in CRC primary formalin-fixed paraffin-embedded tissue. b | MET RNA in situ hybridization in liver metastases from a patient with CRC. c–e | Representative images of c-MET immunohistochemical staining using the CONFIRM SP44 anti-MET rabbit monoclonal antibody in core biopsy samples of CRC liver metastasis showing heterogeneous immunoreactivity (defined as samples with specific regions with a c-MET stratification score of 1+ and others with a score of 3+) for c-MET. Bradley, C. A. et al. (2017) Targeting c‑MET in gastrointestinal tumours: rationale, opportunities and challenges Nat. Rev. Clin. Oncol. doi: /nrclinonc

Download ppt "Nat. Rev. Clin. Oncol. doi: /nrclinonc"

Similar presentations

Figure 1 The heterogenous landscape of triple-negative breast cancer

Figure 1 The heterogenous landscape of triple-negative breast cancer
Reproduced with permission from Cronin M et al

Reproduced with permission from Cronin M et al
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Response after initial increase in total tumour burden

Figure 2 Response after initial increase in total tumour burden
Figure 3 Response after appearance of a new lesion

Figure 3 Response after appearance of a new lesion
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Multiscale modelling in oncology

Figure 2 Multiscale modelling in oncology
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 3 Monitoring clonal evolution using liquid biopsies
Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.
Figure 3 Intracranial targeting of high-grade gliomas

Figure 3 Intracranial targeting of high-grade gliomas
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Copy-number variations in multiple myeloma

Figure 2 Copy-number variations in multiple myeloma
Figure 5 Identification of mucinous carcinoma

Figure 5 Identification of mucinous carcinoma
Figure 3 Natural and imatinib-induced immunosurveillance in gastrointestinal tumours (GISTs) Figure 3 | Natural and imatinib-induced immunosurveillance.

Figure 3 Natural and imatinib-induced immunosurveillance in gastrointestinal tumours (GISTs) Figure 3 | Natural and imatinib-induced immunosurveillance.
Figure 1 The multidomain structure of c-MET and its ligand, HGF

Figure 1 The multidomain structure of c-MET and its ligand, HGF

Similar presentations

Ads by Google